Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;33(5):e12958.
doi: 10.1111/jne.12958. Epub 2021 May 16.

2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly

Ming Shen  1   2   3   4   5   6 , Zhengyuan Chen  1   2   3   4   5 , Xuefei Shou  1   2   3   4   5   6 , Wenqiang He  1   2   3   4   5 , Nidan Qiao  1   2   3   4   5 , Zengyi Ma  1   2   3   4   5 , Zhao Ye  1   2   3   4   5 , Yichao Zhang  1   2   3   4   5 , Qilin Zhang  1   2   3   4   5 , Xiang Zhou  1   2   3   4   5   6 , Xiaoyun Cao  1   2   3   4   5 , Zhaoyun Zhang  5   7   8 , Hongying Ye  5   7 , Yiming Li  5   7 , Yao Zhao  1   2   3   4   5   6   8 , Shiqi Li  1   2   3   4   5 , Min He  5   7 , Yongfei Wang  1   2   3   4   5   6
Affiliations

2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly

Ming Shen et al. J Neuroendocrinol. 2021 May.

Abstract

The present study investigated the factors associated with recurrence during long-term follow-up in acromegaly and compared the recurrence rate between patients in remission with 2010 vs 2000 consensus criteria. We retrospectively recruited 133 adult acromegalic patients who had undergone transsphenoidal surgery (TSS) from January 2013 to December 2014 and assessed their clinical characteristics, surgical outcomes and recurrence. Surgical remission was defined as normalised insulin-like growth factor 1 (IGF-1) with nadir growth hormone (GH) during an oral glucose tolerance test (OGTT) < 1 μg/ L no less than 3 months after TSS without adjuvant therapy. Recurrence was defined as persistently reelevated IGF-1 after surgical remission. Cox regression analysis and Kaplan-Meier survival analysis were performed to evaluate the factors associated with recurrence. Remission was achieved in 77 cases (57.9%) after TSS alone. Recurrence was seen in five cases (6.5%) at 12, 12, 12, 36 and 54 months, respectively, after surgery. Cox regression analysis showed that a nadir GH < 0.4 μg /L (vs 0.4-1.0 μg /L) at surgical remission (odds ratio [OR] = 0.106; 95% confidence interval [CI] = 0.017-0.645; P = 0.015) and Ki-67 index (OR = 2.636; 95% CI = 1.023-6.791; P = 0.045) were independent factors influencing recurrence. Kaplan-Meier survival analysis showed that the median recurrence-free survival was 36 months (95% CI = 20-52) for patients with nadir GH 0.4-1.0 μg /L at surgical remission. The median recurrence-free survival for patients with nadir GH < 0.4 μg /L at surgical remission was much longer (ie, required further follow-up to estimate). A failure of GH suppression under 0.4 μg /L during an OGTT in patients with normalised IGF-1 and a higher Ki-67 index are independent predictors of recurrence after surgical remission in GH-secreting pituitary adenomas. Compared to patients with nadir GH < 0.4 μg /L, those with nadir GH 0.4-1.0 μg /L appear to have a significantly higher risk of recurrence.

Keywords: GH-secreting pituitary adenoma; acromegaly; nadir GH during OGTT; recurrence; surgical remission; transsphenoidal surgery.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167:189-198.
    1. Mercado M, Gonzalez B, Vargas G, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99:4438-4446.
    1. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61-67.
    1. Maione L, Brue T, Beckers A, et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017;176:645-655.
    1. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.

Substances

LinkOut - more resources